|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0035412,
umls-concept:C0036525,
umls-concept:C0042679,
umls-concept:C0087111,
umls-concept:C0123931,
umls-concept:C0205195,
umls-concept:C0205390,
umls-concept:C0557702,
umls-concept:C1516477,
umls-concept:C1522484,
umls-concept:C1707491
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-1-31
|
|
pubmed:abstractText |
To estimate the antitumor activity and toxicity of irinotecan alone and in combination with vincristine when administered as window therapy and in combination with standard chemotherapy in pediatric patients with newly diagnosed metastatic rhabdomyosarcoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
362-9
|
|
pubmed:dateRevised |
2007-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:17264331-Adolescent,
pubmed-meshheading:17264331-Adult,
pubmed-meshheading:17264331-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17264331-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17264331-Camptothecin,
pubmed-meshheading:17264331-Child,
pubmed-meshheading:17264331-Child, Preschool,
pubmed-meshheading:17264331-Combined Modality Therapy,
pubmed-meshheading:17264331-Cyclophosphamide,
pubmed-meshheading:17264331-Dactinomycin,
pubmed-meshheading:17264331-Drug Administration Schedule,
pubmed-meshheading:17264331-Female,
pubmed-meshheading:17264331-Humans,
pubmed-meshheading:17264331-Infant,
pubmed-meshheading:17264331-Male,
pubmed-meshheading:17264331-Neoplasm Metastasis,
pubmed-meshheading:17264331-Rhabdomyosarcoma,
pubmed-meshheading:17264331-Treatment Outcome,
pubmed-meshheading:17264331-Vincristine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
|
|
pubmed:affiliation |
Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. aspappo@txccc.org
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
